Dotmatics, eMolecules Announce Partnership
News Apr 20, 2016
Dotmatics, a leading provider of scientific informatics solutions and services to the life sciences industry, and eMolecules have announced that they have formed a key partnership to offer eMolecules’ comprehensive collection of chemicals within the powerful, fast and flexible Dotmatics Platform.
The result of the partnership will be a new Dotmatics eMolecules component that will enable users to select chemical compounds for sourcing, enhancing drug discovery, or chemistry research.
Users of Vortex, Browser and Studies Notebook will now be able to benefit from the full eMolecules collection of chemical compounds enhanced with additional chemistry property data provided by the Dotmatics chemistry platform.
In the last 10 years, eMolecules has become the most widely adopted chemical sourcing database used by the pharmaceutical, biotechnology and chemical industries. The wide coverage of building blocks and screening compounds collated from hundreds of vendors has led to it becoming a trusted source of chemistry information in the industry. The eMolecules database contains more than 7 million unique chemicals and more than 20 million products including different packaging and suppliers.
Dotmatics powerful chemically intelligent search engine enables users to query, search and retrieve results across the entire eMolecules database in seconds. Users will be able to rapidly search and identify compounds, available quantities, indicative pricing, and suppliers. In Browser they will be able to easily compare compounds and products from different vendors and make informed decisions about which compounds to purchase.
eMolecules’ data has been enriched with additional properties including matched molecular pairs, protecting group information and predicted properties provided by the Dotmatics platform. These benefits, available exclusively in the new component, will enable scientists to make the most appropriate decisions when selecting compounds for a synthesis or screening.
In addition, using the results from the compound lists generated by the Dotmatics-eMolecules component, organisations can simplify their sourcing and procurement process by using eMolecules’ fulfilment services directly.
“This partnership brings together a sophisticated database and our powerful search technology,” said Mike Hartshorn, PhD, Chief Science Officer of Dotmatics. “The chemical industry provides most of the raw material and products we use today from reagents to screening compounds; together with eMolecules, we will help customers easily manage the huge amount of data available for compound procurement”.
“Dotmatics is an ideal partner due to their extensive capabilities in knowledge management, data storage enterprise query and reporting, data analysis, and visualization,” said Niko Gubernator, PhD, CEO of eMolecules. “Together our companies are uniquely poised to empower researchers to accelerate chemical discovery.”
MIT researchers have developed a cryptographic system that could help neural networks identify promising drug candidates in massive pharmacological datasets, while keeping the data private. Secure computation done at such a massive scale could enable broad pooling of sensitive pharmacological data for predictive drug discovery.
Biochemists, microbiologists, drug discovery experts and infectious disease doctors have teamed up in a new study that shows antibiotics are not always necessary to cure sepsis in mice. Instead of killing causative bacteria with antibiotics, researchers treated infected mice with molecules that block toxin formation in bacteria.READ MORE